Old Web
English
Sign In
Acemap
>
authorDetail
>
Todd A. Busman
Todd A. Busman
AbbVie
Medicine
Mantle cell lymphoma
Neutropenia
Immunology
Progressive disease
3
Papers
113
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
2017
Journal of Clinical Oncology
Matthew S. Davids
John F. Seymour
John F. Gerecitano
Brad S. Kahl
John M. Pagel
William G. Wierda
Mary Ann Anderson
David E. Darden
Cathy E. Nolan
Lori A. Gressick
Jianning Yang
Brenda Chyla
Todd A. Busman
Alison M. Graham
Elisa Cerri
Sari H. Enschede
Rod A. Humerickhouse
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (11)
The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients
2013
Blood
Matthew S. Davids
John F. Seymour
John F. Gerecitano
Brad S. Kahl
John M. Pagel
William G. Wierda
Mary Ann Anderson
Nikita Rudersdorf
Lori A. Gressick
Nicholas P. Montalvo
Jianning Yang
Todd A. Busman
Martin Dunbar
Elisa Cerri
Sari H. Enschede
Rod A. Humerickhouse
Andrew W. Roberts
Show All
Source
Cite
Save
Citations (42)
1